Buntanetap improved cognition in pTau217-positive early AD patientsThe drug reduced neurotoxic proteins as well as biomarkers of ...

Newleos doses the first participant in a Phase 1b study of NTX-2001, a potential first-in-class TAAR1 partial agonist for ...

Incyte’s povorcitinib has scored a pair of phase 3 wins for a skin condition, although analysts noted the oral JAK inhibitor ...

On April 2, Beam Therapeutics Inc. (NASDAQ:BEAM) released results from its Phase 1/2 BEACON study for ristoglogene ...

Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines ...

Boehringer Ingelheim’s glucagon/GLP-1 dual agonist has driven 16.6% weight loss at Week 76 of a phase 3 study. While the ...

Topline results from the pivotal HAELO trial demonstrate that a single infusion of lonvo-z significantly reduces HAE attacks and the need for chronic prophylactic therapy.

The trial involved adults and adolescents aged 12 years and above with MOGAD, offering an open-label extension.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced the primary endpoint was met in the Phase 2b portion of the AZURE-1 study evaluating brelovitug, an ...

Pharvaris has initiated CHAPTER-3, a pivotal Phase 3 study of deucrictibant designed to prevent hereditary angioedema (HAE) attacks, with topline data expected by the second half of 2026. The company ...

U.S. Phase II study is evaluating the efficacy, safety and tolerability of oral small molecule GLP-1R agonist ASC30, a ...

Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness ...